Skip to main content

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Publication ,  Journal Article
Desjardins, A; Reardon, DA; Herndon, JE; Marcello, J; Quinn, JA; Rich, JN; Sathornsumetee, S; Gururangan, S; Sampson, J; Bailey, L; Bigner, DD ...
Published in: Clin Cancer Res
November 1, 2008

PURPOSE: Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma. EXPERIMENTAL DESIGN: Upon documentation of adequate safety among an initial cohort of nine patients treated with bevacizumab (10 mg/kg) and irinotecan every 14 days, a second cohort (n=24) was treated with bevacizumab (15 mg/kg) every 3 weeks with irinotecan on days 1, 8, 22, and 29 of each 42-day cycle. For both cohorts, the dose of irinotecan was 340 mg/m(2) for patients on enzyme-inducing antiepileptic drugs (EIAED) and 125 mg/m(2) for patients not on EIAEDs. After each 6-week cycle, patients were evaluated with a physical examination and magnetic resonance imaging. RESULTS: The 6-month progression-free survival was 55% (95% confidence interval, 36-70%). The 6-month overall survival was 79% (95% confidence interval, 61-89%). Twenty patients (61%) had at least a partial response. Outcome did not differ between the two treatment cohorts. Significant adverse events were infrequent and included a central nervous system hemorrhage in one patient, and one patient who developed thrombotic thrombocytopenic purpura. CONCLUSION: Bevacizumab and irinotecan is an active regimen with acceptable toxicity for patients with recurrent WHO grade 3 malignant glioma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

November 1, 2008

Volume

14

Issue

21

Start / End Page

7068 / 7073

Location

United States

Related Subject Headings

  • Survival Analysis
  • Recurrence
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Irinotecan
  • Humans
  • Glioma
  • Female
  • Disease-Free Survival
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Reardon, D. A., Herndon, J. E., Marcello, J., Quinn, J. A., Rich, J. N., … Vredenburgh, J. J. (2008). Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res, 14(21), 7068–7073. https://doi.org/10.1158/1078-0432.CCR-08-0260
Desjardins, Annick, David A. Reardon, James E. Herndon, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, et al. “Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.Clin Cancer Res 14, no. 21 (November 1, 2008): 7068–73. https://doi.org/10.1158/1078-0432.CCR-08-0260.
Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008 Nov 1;14(21):7068–73.
Desjardins, Annick, et al. “Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.Clin Cancer Res, vol. 14, no. 21, Nov. 2008, pp. 7068–73. Pubmed, doi:10.1158/1078-0432.CCR-08-0260.
Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008 Nov 1;14(21):7068–7073.

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

November 1, 2008

Volume

14

Issue

21

Start / End Page

7068 / 7073

Location

United States

Related Subject Headings

  • Survival Analysis
  • Recurrence
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Irinotecan
  • Humans
  • Glioma
  • Female
  • Disease-Free Survival